Shares of Caribou Biosciences (NASDAQ: CRBU) were crashing 19.7% lower as of 11:13 a.m. ET on Tuesday. The big sell-off came after the biotech provided its fourth-quarter update on Monday.
Caribou reported fourth-quarter licensing revenue of $3.6 million and a net loss of $34.5 million. However, the big story with the clinical-stage biotech’s quarterly update was the pause in developing allogeneic cell therapy CB-020.
How worrisome is Caribou Biosciences’ development pause?
It’s not surprising that Caribou’s shares fell on the news about pausing the development of CB-020. But just how worrisome is this for investors?
To be sure, any winnowing of Caribou’s pipeline isn’t great. The company has just three programs in clinical development right now, all of which are in early-stage clinical studies. Investors prefer more shots on goal rather than fewer opportunities.
On the other hand, CB-020 was only in preclinical testing. Importantly, Caribou didn’t say it was completely throwing in the towel on the program. The company chose its words carefully in the announcement, stating that it had “paused the development” rather than halted all future development. Caribou also said that it will continue to develop its CAR-NK (chimeric antigen receptor-natural killer) cell therapy platform “as these therapies may have potential for the treatment of multiple diseases.”
Is Caribou Biosciences a buy on the pullback?
Today’s sell-off presents a good buying opportunity, in my view, for aggressive investors who are willing to bet on Caribou’s success over the long term. I don’t think that the pausing of the development of CB-020 affects the prospects for the biotech stock as much as the decline seems to reflect.
Caribou Biosciences isn’t a good fit for risk-averse investors, though. There’s no guarantee that the company’s pipeline candidates will make it to market. Other stocks offer better risk-reward profiles.
Should you invest $1,000 in Caribou Biosciences right now?
Before you buy stock in Caribou Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Caribou Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of March 11, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Caribou Biosciences. The Motley Fool has a disclosure policy.
Why Caribou Biosciences Stock Is Crashing Today was originally published by The Motley Fool
Signup bonus from
